Silence’s stock soars on divesiran’s Phase II polycythaemia vera success

Phase 2positivedivesiranPositive

AI Analysis

Summary

Silence Therapeutics' divesiran achieved Phase II success in polycythaemia vera, positioning it as a potential first siRNA therapy in an indication currently dominated by Jakafi and Besremi. The positive results drove a significant stock price increase.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Met

Outcome Details

Phase II success in polycythaemia vera

Importance:7/10

Sentiment:

0.85

siRNA therapypolycythaemia verarare diseasePhase 2 dataJakafiBesremi

Related Companies

$TRAX $ARNA $VERA

Read the original article

Published by Clinical Trials Arena on August 11, 2026 1:55 PM

Read Original